Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others.

Pharmaceutical

Olatec Therapeutics

Olatec Therapeutics' headquarters in New York, NY, United States

Damaris B. Skouras

Sophia Hughes

Piscitelli Philip

Cynthia (Dana) Barrow

Charles A. Dinarello

Robert H. Dworkin

Steven B. Newhard

Shayne C. Gad

Leo A. B. Joosten

Howard I. Maibach

Alberto Mantovani

F. Kip Vought

Timotheus Jansen

Jose Ángel Cordova Villalobos

Matthijs Janssen

Antonio Abbate

William J. Cunningham

Lucio C. Rovati

Craig T. Basson

Spyros S. Skouras, Jr.

Valentín Campos, Sr.

John F. Otto

George A. Skouras

Andrea Leonard-Segal

Peter Libby

Viola T. Kung

Marc J. Philippon

Amy K. Poshusta

Daniel Yadegar

Robert M. Fielding

Gregory K. Palm

The Scientific Advisors at Olatec Therapeutics are tasked with providing expert guidance on the design, development, and implementation of research projects related to NLRP3 antagonist therapeutics. They leverage their extensive knowledge in immunology and pharmacology to help shape clinical strategies, support regulatory submissions, and ensure that the scientific integrity of the company's therapeutic innovations is maintained. By collaborating with cross-functional teams, they aim to advance Olatec’s mission of addressing a wide range of inflammatory diseases.

Scientific Advisors

This department oversees strategic direction and decision-making within the organization.

Leadership

The Clinical Advisors team at Olatec Therapeutics provides expert guidance on the design and execution of clinical trials for the company's NLRP3 antagonist therapeutics. They collaborate with cross-functional teams to ensure that clinical strategies align with regulatory requirements and scientific goals, while also interpreting clinical data to inform the development of treatments for inflammatory diseases. Their insights help drive the advancement of innovative therapies from the lab to clinical practice.

Clinical Advisors

This department is responsible for overseeing the organization's policies, practices, and compliance at the board level.

Board Governance

The Clinical Development team at Olatec Therapeutics is responsible for designing and implementing clinical trials to evaluate the safety and efficacy of the company's innovative NLRP3 antagonist therapeutics. This team collaborates closely with cross-functional partners to ensure compliance with regulatory standards, optimize trial designs, and analyze clinical data, ultimately advancing the development of therapies for a range of inflammatory diseases. Their efforts are essential for bringing new treatment options to patients and supporting the company's mission of addressing unmet medical needs.


Clinical Development

This department oversees corporate strategies and research and development initiatives.

Corporate Affairs

Olatec Therapeutics

Org chart

Board & advisors

Teams

Scientific Advisors

Leadership

Clinical Advisors

Board Governance

Clinical Development

Corporate Affairs

Offices

Olatec Therapeutics

Org chart

Board & advisors

Teams

Scientific Advisors

Leadership

Clinical Advisors

Board Governance

Clinical Development

Corporate Affairs

Offices

Related companies